Top Markets
#1 Bedrock Bedrock +42.69%
#2 Talus Network Talus Network +24.65%
#3 API3 API3 +20.65%
#4 CyberDEX CyberDEX +19.21%
#5 iExec RLC iExec RLC +18.52%
#6 Radicle Radicle +16.37%
#7 The Bitcoin Bull The Bitcoin Bull +16.37%
#8 VeThor VeThor +13.05%
#9 Verus Coin Verus Coin +11.08%
#10 Rollbit Coin Rollbit Coin +10.44%
Coin of the day
Bedrock Bedrock
設定
言語
日本
通貨
USD
テーマ
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
株式のランク #28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
株価
$0.4
最終同期: 2026-10-02
時価総額
$27.18M
変化（1日）
-14.88%
変化（1年）
8.11%
国
US
取引 Cell Source, Inc. (CLCS)

カテゴリー

Healthcare
Cell Source, Inc.（CLCS）の配当利回りの履歴
Cell Source, Inc.（銘柄コード: CLCS）の配当利回り（TTM）は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Cell Source, Inc.（CLCS）の2026から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
年 配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り（TTM）
企業 配当利回り 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.27%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH